期刊文献+

CTCF过表达对乳腺癌细胞凋亡因子Bax和Bcl-2表达的影响 被引量:1

Effects of overexpression of CTCF on apoptosis factors Bax and Bcl-2 in breast cancer cells
下载PDF
导出
摘要 目的探讨CTCF过表达对人乳腺癌细胞系MDA-MB-231中细胞凋亡因子Bax和Bcl-2表达的影响。方法用逆转录聚合酶链式反应(RT-PCR)检测人乳腺癌细胞系MDA-MB-231中CTCF、Bax和Bcl-2的表达。构建CTCF/pEGFP-N1过表达载体,用慢病毒转染法分别将CTCF/p EGFP-N1和空载质粒转入MDA-MB-231中,记作CTCF组和对照组。经RT-PCR鉴定CTCF成功转染MDA-MB-231后,采用实时定量PCR(Q-PCR)检测CTCF组和对照组MDA-MB-231中Bax和Bcl-2的mRNA表达,Western blot和酶联免疫吸附试验(ELISA)检测Bax和Bcl-2的蛋白表达。结果 MDA-MB-231中不表达CTCF,表达Bax和Bcl-2。Q-PCR结果显示,CTCF组、对照组中Bax的mRNA表达水平分别为4.63±1.08和2.27±0.16,2组间差异有统计学意义(t=27.50,P<0.05);Bcl-2的mRNA表达水平分别为1.39±0.14和3.56±0.97,2组间差异有统计学意义(t=39.00,P<0.05)。Western blot结果显示,CTCF组中Bax蛋白表达水平高于对照组,Bcl-2蛋白水平低于对照组。ELISA结果显示,CTCF组和对照组中Bax蛋白表达水平分别为15.25±2.17和6.24±1.78,2组间差异有统计学意义(t=26.84,P<0.05);Bcl-2蛋白表达水平分别为4.59±0.97和10.68±1.93,2组间差异有统计学意义(t=21.72,P<0.05)。结论 CTCF过表达可促进乳腺癌细胞中凋亡因子的表达,抑制抗凋亡因子的表达。 Objective To investigate the effect of the over-expressed CTCF on apoptosis factors Bax and Bcl-2 inhuman breast cancer cell line MDA-MB-231. Methods Reverse transcription-polymerase chain reaction(RT-PCR) wereused to detect the expressions of CTCF,Bax and Bcl-2 in MDA-MB-231. The overexpression vector of CTCF/p EGFP-N1 was constructed. The overexpression plasmid CTCF/pEGFP-N1 and the empty vector plasmid p EGFP-N1 were transfectedinto breast cancer cell line MDA-MB-231 by lentivirus transfection, and the MDA-MB-231 cells were divided into CTCFgroup and control group. After successfully transfection of MDA-MB-231 identified by RT-PCR, real time quantitative PCR(Q-PCR) was used to detect the mRNA levels of Bax and Bcl-2 in MDA-MB-231 of the CTCF group and the control group.The protein levels of Bax and Bcl-2 were detected by Western blot assay and enzyme-linked immunosorbent assay(ELISA).Results The expression of CTCF was not found in MDA-MB-231, and expressions of Bax and Bcl-2 were found in MDA-MB-231. Results of Q-PCR showed that the mRNA levels of Bax were 4.63±1.08 and 2.27±0.16 in CTCF group and controlgroup, respectively, and they were statistically significant(t=27.50, P<0.05). The mRNA levels of Bcl-2 were 1.39±0.14 and3.56± 0.97 in CTCF group and control group, and there was significant difference between two groups(t=39.00, P<0.05).Results of Western blot assay showed that the protein level of Bax was higher in CTCF group compared with that of controlgroup. The protein level of Bcl-2 was lower in CTCF group compared with that of control group. Results of ELISA showedthat the protein levels of Bax were 15.25±2.17 and 6.24±1.78 in CTCF group and control group, respectively, and there wassignificant difference between the two groups(t=26.84, P<0.05). The protein levels of Bcl-2 were 4.59±0.97 and 10.68±1.93, and there was significant difference between the two groups(t=21.72, P<0.05). Conclusion The over-expressedCTCF can promote the expression of apoptotic factors and inhibit the expression of anti-apoptotic factors in breast cancer cells.
出处 《天津医药》 CAS 2017年第10期1009-1012,共4页 Tianjin Medical Journal
关键词 乳腺肿瘤 BCL-2相关X蛋白质 基因 BCL-2 CTCF 凋亡因子 breast neoplasms bcl-2-associated X protein genes,bcl-2 CTCF apoptosis factors
  • 相关文献

参考文献2

二级参考文献16

  • 1Kim TH1, Abdullaev ZK, Smith AD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome [J]. Cell, 2007, 128:1231-1245.
  • 2Merkenschlager M, Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets [ J ]. Cell, 2013, 152-1285-1297.
  • 3Ong CT, Corces VG. CTCF: an architectural protein bridg- ing genome topology and function [ J ]. Nat Rev Genet, 2014, 15:234-246.
  • 4Fiorentino FP, Giordano A. The tumor suppressor role of CTCF [J]. J Cell Physiol. 2012. 227.479-492.
  • 5Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? [ J ]. Breast Cancer Res, 2002, 4:5-8.
  • 6Green, AR, Krivinskas S, et al. Loss of expression of chro- mosome 16q genes DPEP1 and CTCF in lobular carcinomain sitn of the breast [ J ]. Breast Cancer Res Treat, 2009, If3: 59-66.
  • 7Tiffen JC, Bailey CG, Marshall AD, et aL The cancer-tes- tis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic ceils [J]. Int J Cancer, 2013, 133 : 1603-1613.
  • 8Yoshida K, Toki T, Okuno Y, et al. The landscape of so- matic mutations in Down syndrome-related myeloid disor- ders [J]. Nat Genet, 2013, 45:1293-1299.
  • 9Marshall AD, Bailey CG, Rasko JE. CTCF and BORIS in genome regulation and cancer. [ J ]. Curt Opin Genet Dev, 2014, 24:8-15.
  • 10Torrano V, Chernukhin I, Doequier F, et al. CTCF regu- lates growth and erythroid differentiation of human myeloid leukemia cells [ J ]. J Biol Chem, 2005, 280: 28152-28161.

共引文献10

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部